Omega Ophthalmics Raises $7M Series A for Gemini Capsule
Fundraise Insider tracks newly funded startups each week and delivers verified sales leads of C-suite contacts straight to your inbox, so you reach the right people while the funding is still fresh. See pricing.
Omega Ophthalmics has closed a $7 million Series A financing, and the Lexington, Kentucky company intends to put the money toward getting its Gemini Refractive Capsule in front of United States regulators. A group of strategically aligned ultra high net worth investors led the round.
The announcement arrived alongside a second piece of news. Omega has scheduled its FDA presubmission meeting, an early exchange in which the company can align its proposed regulatory pathway and its clinical development plans with feedback from the FDA review team. Omega says it intends to stay in close communication with the agency as it works toward beginning clinical studies in the United States.
The new capital is earmarked for continued product development, intellectual property, regulatory activities, manufacturing scale up and clinical planning, all of it groundwork for future FDA studies and eventual commercialization.
Omega describes itself as a medical technology company building implant technology for the next phase of cataract surgery. Its Gemini Refractive Capsule is designed to offer a stable, biologically integrated platform for intraocular lens implantation while preserving the capsular bag. According to the company, that approach carries the potential to improve long term refractive stability, permit lens exchange at a later date, and accommodate ophthalmic technologies that have yet to arrive. In a medical device category where an implant is expected to remain in place for years, that kind of flexibility is not a small claim.
The company has been making its case publicly as well. At the Octane Ophthalmology Tech Forum, chief operating officer John Sheets, Jr., Ph.D., presented Omega’s vision and clinical development strategy to an audience of investors, industry leaders and strategic partners.
Sales teams and vendors that sell into medical technology and life science companies can pull verified contacts at newly funded startups every week through Life Science Lead Generation.